Larimar Therapeutics, Inc.
LRMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.15 | 0.06 | 0.21 |
| FCF Yield | -30.07% | -16.83% | -26.01% | -22.91% |
| EV / EBITDA | -2.31 | -4.31 | -2.35 | -2.42 |
| Quality | ||||
| ROIC | -51.37% | -47.85% | -31.40% | -71.67% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.91 | 0.78 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -111.98% | -21.52% | 34.80% | -0.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 0.51 | 0.59 | 1.28 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |